Systemic Lupus Erythematosus (SLE) is a chronic, heterogeneous autoimmune disease characterized by a loss of immune tolerance, production of autoantibodies, and multi-organ inflammation. For decades, management relied heavily on corticosteroids and broad-spectrum immunosuppressants, often with significant toxicity. This review provides a comprehensive overview of SLE, with a particular emphasis on the revolution in therapeutic strategies driven by an improved understanding of its immunopathogenesis. We detail the key pathogenic pathways, including dysregulated B and T cell activity, the central role of the type I interferon signature, and innate immune activation. The review then focuses on the modern treatment paradigm, which aims for a "treat-to-target" approach to achieve remission or low disease activity while minimizing steroid exposure. We expand in detail on the foundational role of hydroxychloroquine, the standard use of mycophenolate mofetil in lupus nephritis, and the transformative impact of biologic agents. These include belimumab (a B-lymphocyte stimulator inhibitor), anifrolumab (a type I interferon receptor antagonist), and the recent approval of voclosporin for nephritis. Finally, we explore emerging therapies targeting novel pathways, which promise a future of personalized, precision medicine for SLE patients. The evolution from non-specific immunosuppression to targeted biologic therapy marks a new era of improved outcomes and quality of life for individuals living with this complex disease.
Hussien Abouelhag (Tue,) studied this question.